Recent Updates — BGM

BGM Group Ltd. announced a 30-for-one share consolidation to be effective October 1, 2026, following shareholder approval on September 5, 2026. The transaction reduces outstanding Class A ordinary shares from approximately 380.6 million to roughly 12.7 million and increases the par value of all share classes from US$0.0001 to US$0.003. Fractional shares will be rounded up to whole shares, and authorized capital is adjusted accordingly. BGM Group Ltd. operates in the beauty and personal care industry.

BGM Group Ltd filed its unaudited financial results for the six months ended March 31, 2026. The company reported net revenue of $24,295,443, a significant increase from $14,311,414 in the prior year period. However, the company posted a net loss attributable to BGM Group Ltd of $(2,104,348), compared to a net loss of $(861,220) in the same period last year. Gross profit rose to $4,307,554 from $2,511,433, while selling, general and administrative expenses increased to $5,185,455. Total assets stood at $436,546,938 as of March 31, 2026. The company operates in the biopharmaceuticals, traditional Chinese medicine derivatives, and AI technology sectors.

BGM Group Ltd is convening an Extraordinary General Meeting on September 5, 2026, to approve a 30-for-1 reverse share consolidation and increase authorized share capital from US$503,000 to US$15,090,000. These resolutions replace previous approvals that were deemed invalid under Cayman Islands law because they improperly delegated share capital alteration authority to the Board. The meeting also seeks approval for amendments to the company's memorandum and articles of association to reflect these changes. BGM Group Ltd operates in the beauty industry.

BGM Group Ltd announced the resignation of Mr. Chen Xin as Chairman of the Board and Co-Chief Executive Officer, effective July 30, 2026, citing personal reasons without any dispute with the company. The board appointed his father, Mr. Zhanchang Xin, as the new Chairman of the Board, leveraging over 35 years of pharmaceutical industry experience. Additionally, Ms. Hong Li was appointed as Co-Chief Executive Officer effective July 30, 2026, bringing extensive financial management and accounting expertise from her tenure at Gansu Qilianshan Pharmaceutical Co. Ltd. These leadership changes represent a significant transition in the company's executive structure.

BGM Group Ltd. regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Form 20-F annual report for the fiscal year ended September 30, 2025, on July 21, 2026. The Nasdaq Staff confirmed compliance on July 24, 2026, resolving the deficiency that arose from the delayed filing. The company operates in the biotechnology and pharmaceutical industry.